echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Okvision's tyrosine kinase inhibitor is first approved for clinical treatment of dry eye

    Okvision's tyrosine kinase inhibitor is first approved for clinical treatment of dry eye

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On October 12, the CDE official website showed that the clinical trial application of Ou Kangweishi OT202 eye drops was approved by the Food and Drug Administration for the first time for the treatment of dry eye


    Dry eye is a chronic ocular surface disease caused by multiple factors.


    The key treatment for dry eye is to break the vicious circle of inflammation


    OT202 eye drops is a tyrosine kinase inhibitor independently developed by Okvision.


    Source: Ou Kangweishi official website

    At present, Ou Kangweishi has 4 dry eye drugs under development, namely OT-202, OT-204, OT-503, and OT-1301


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.